tanezumab

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 470477328

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu/o

| target = Nerve growth factor (NGF)

| tradename =

| pregnancy_AU =

| pregnancy_category =

| routes_of_administration =

| ATC_prefix = N02

| ATC_suffix = BG12

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 880266-57-9

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB12335

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = EQL0E9GCX1

| synonyms = RN624

| C=6464 | H=9942 | N=1706 | O=2026 | S=46

}}

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs.{{cite journal | vauthors = Oo WM, Hunter DJ | title = Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review | journal = BioDrugs | volume = 35 | issue = 6 | pages = 611–641 | date = November 2021 | pmid = 34807432 | doi = 10.1007/s40259-021-00504-8 | s2cid = 244509341 }} Tanezumab was discovered and developed by Rinat Neuroscience{{cite journal | vauthors = Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A | title = Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis | journal = Pain | volume = 116 | issue = 1–2 | pages = 8–16 | date = July 2005 | pmid = 15927377 | doi = 10.1016/j.pain.2005.03.039 | s2cid = 36145654 }} and was acquired by Pfizer in 2006.

In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).{{ClinicalTrialsGov|NCT00733902|Tanezumab in Osteoarthritis of the Knee}}

Another Phase III trial for hip pain in OA{{ClinicalTrialsGov|NCT00744471|Tanezumab in Osteoarthritis Of The Hip}} was halted in June 2010 when some patients needed hip replacement.{{cite web | title = Trials Halted as Pfizer's Tanezumab Shown to Worsen Osteoarthritis | date = 24 June 2010 | work = Genetic Engineering & Biotechnology News | url = http://www.genengnews.com/gen-news-highlights/trials-halted-as-pfizer-s-tanezumab-shown-to-worsen-osteoarthritis/81243572/ | archive-url = https://web.archive.org/web/20130123043725/http://www.genengnews.com/gen-news-highlights/trials-halted-as-pfizer-s-tanezumab-shown-to-worsen-osteoarthritis/81243572/ | archive-date = 23 January 2013 }}

Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.{{cite web |url=http://www.clinicaltrials.gov/ct2/results?term=Tanezumab&phase=1 |title=Phase II trials involving Tanezumab | work = ClinicalTrials.gov | publisher = U.S. National Library of Medicine }}

In March 2012, the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.{{cite web | title = Tanezumab Arthritis Advisory Committee Briefing Document | date = 8 February 2012 | publisher = US Food and Drug Administration | url = https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM295205.pdf | archive-url = https://web.archive.org/web/20170119055305/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM295205.pdf | archive-date = 19 January 2017 }}{{cite web | vauthors = Verburg K | title = Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain | work = Medicines Development Group, Pfizer Inc. | url = https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm301305.pdf | archive-url = https://web.archive.org/web/20170509180502/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM301305.pdf | archive-date = 9 May 2017 }}

A Phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.{{cite journal | vauthors = Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR | title = Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial | journal = Arthritis and Rheumatism | volume = 65 | issue = 7 | pages = 1795–1803 | date = July 2013 | pmid = 23553790 | doi = 10.1002/art.37950 | doi-access = free }}

At February 19, 2019 the co-development partners - Eli Lilly and Pfizer - announced that treatment with tanezumab 10 mg met the primary endpoint, demonstrating a statistically significant improvement in chronic low back pain at 16 weeks compared to placebo (however, 5 mg arm demonstrated a numerical improvement in pain, but did not reach statistical significance compared to placebo at the week 16 analysis).{{cite web|url=https://seekingalpha.com/pr/17415547-pfizer-lilly-announce-top-line-results-phase-3-study-tanezumab-chronic-low-back-pain|title=Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain | date = February 19, 2019 | publisher = PR Newswire |website=Seeking Alpha}}